In an update posted today, Neurogene said that the "emerging treatment-related serious adverse event (SAE)" was a case of ...
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy programme, as per an 18 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback